|Awarded On||November 19, 2014|
|Title||Targeting the SWI/SNF chromatin-remodeling complex in liver cirrhosis and hepatocellular carcinoma|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Hao Zhu|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
Hepatocellular carcinoma (HCC) is a significant cause of cancer-related death worldwide and Texas has the second highest HCC incidence rate in the US. Cirrhosis is the strongest risk factor for HCC, and without cirrhosis, there would be few cases of HCC. Thus, the challenge is twofold: 1) to develop effective therapies for cirrhosis, and 2), to develop effective HCC drugs that do not harm the cirrhotic liver.
Recently, we identified a pathway that when suppressed, results in better liver regeneration and can potentially inhibit HCC. Mice defective for a gene called Arid1a, part of the SWI/SNF gene family that normally regulates the physical scaffold of the genome, showed increased liver cell...